Šīs tīmekļa vietnes satura kvalitātes uzlabošanai un pielāgošanai lietotāju vajadzībām tiek lietotas sīkdatnes - tai skaitā arī trešo pušu sīkdatnes. Turpinot lietot šo vietni Jūs piekrītat sīkdatņu lietošanai.
“Grindeks” has doubled its profit in the first quarter of 2008
Emitents Grindeks, AS (5299006DWR32NKWM1O86)
Veids Finanšu pārskati
Valoda EN
Statuss Publicēts
Versija
Datums 2008-05-08 09:18:27
Versijas komentārs
Teksts
JSC “Grindeks” non-audited consolidated financial report about the results of the first quarter of 2008, presented to Riga Stock Exchange, shows that the Group of “Grindeks” has worked successfully during the first three months of this year. Net profit in the accounting period amounted to 3.5 million lats, twice exceeding the results of the first quarter of 2007. Turnover of the Group amounted to 17 million lats, which is by 5.1 million lats or 43% more than during the first three months of 2007.

Chairman of the Board of “Grindeks” Janis Romanovskis notes: “In the first quarter of 2008 the most substantial part of the profit gave “Grindeks” ready-made medications sales increase by 48%, which, on its turn, was influenced by the fact that in February and March the Russian company “Pharmstandard” purchased from our company a remarkable amount of products to ensure safety stocks and to cope with the initial demand of the Russian pharmaceutical distribution network.” Chairman Board of “Grindeks” forecasts that sales increase will not preserve so high pace during the next quarters.

As earlier announced, in the beginning of 2008 “Grindeks” concluded a collaboration agreement with “Pharmstandard”, one of the leading pharmaceutical companies in Russia. According to the agreement, “Pharmstandard” has obtained exclusive rights to distribute and promote “Grindeks” original product Mildronate® in the Russian Federation since 1 February 2008.

Positive measures of profit were also obtained as the result of increase in export of active pharmaceutical ingredients (API) that reached 1.2 million lats in the first quarter of 2008, similar to the first three months of 2007. Chairman of the Board of “Grindeks” Janis Romanovskis stressed that ftorafur, zopiclone, oxytocin and rilmenidine and the new veterinary product detomidine are the most marketable products among the active pharmaceutical ingredients of “Grindeks” at the moment. Besides, “Grindeks” has gained 35% of the world market by exporting zopiclone and oxytocin, but the sales of veterinary substance detomidine in the EU countries already make 49% of the EU market.

In March JSC “Grindeks” has concluded a contract with one of America’s most distinguished Research Centers - Wake Forest University School of Medicine - on supply of active pharmaceutical ingredient oxytocin for the project of new anaesthetic scientific research. It is a big recognition to “Grindeks” product quality, because the USA is one of the world’s most particular countries about quality demands.

Overview of JSC “Grindeks”

JSC “Grindeks” is the leading pharmaceutical company in the Baltic States. Its main activity is research, development, production and sales of original products, generics and active pharmaceutical ingredients. “Grindeks” specializes in the heart and cardiovascular, CNS and anti-cancer medication therapeutic groups.

A range of “Grindeks” products covers a successful combination of original products and generics. It includes the original products Mildronate® and Ftorafur® and more than 100 forms of effective and safe generics.

The Group of “Grindeks” consists of four subsidiary companies in Latvia, Estonia and Russia. It has representatives and representative offices in fourteen countries. Products of the company are exported to more than 40 countries and its export comprises more than 92% of the total turnover. The main markets are the Baltic States, Russia and CIS countries, Japan, the USA. JSC “Grindeks” shares are listed in the Official List of Riga Stock Exchange.

You are kindly invited to www.grindeks.lv to get to know more about our company!

Further information:
Solvita Ulmane
“Grindeks” Communications Department
E-mail: solvita.ulmane@grindeks.lv
Phones: (+371) 67083448
www.grindeks.lv
Pielikumi
Grindeks_non-audited_report_2008 1 Q.pdf (87.18 kB)